Call to Schedule Free Consultation at Over 80 Centers Worldwide!

(844) GET-STEM

Stem Cell Therapy and Cancer Risk: A Review of the Current Evidence

Written by Dr. David Greene, MD, PhD, MBA on October 12, 2026

Table of Contents

As regenerative medicine gains attention worldwide, one question comes up more than any other among prospective patients:can stem cell therapy increase the risk of cancer?

Clinics now market mesenchymal stem cells (MSCs) for conditions ranging from autoimmune disease and joint degeneration to recovery after vascular injury. That makes it important to separate marketing claims from peer-reviewed safety data. This article summarizes what is currently known about MSC safety, where uncertainty remains, and how to evaluate a provider.

The Short Answer

Current clinical evidence does not show that properly processed, unmanipulated MSCs cause cancer or form primary tumors in recipients. However,“no evidence of harm” is not the same as “proven safe in every context.” Long-term data are still limited, and important precautions apply, particularly for anyone with a history of cancer.

Not All Stem Cells Carry the Same Risk

Much of the public concern comes from confusing different cell types:

Embryonic stem cells (ESCs) are pluripotent, meaning they can become almost any cell type. If undifferentiated ESCs are administered, they can form teratomas, a type of tumor. This is the main source of the "stem cells cause tumors" reputation.

Mesenchymal stem cells (MSCs) are multipotent cells sourced from umbilical cord tissue (Wharton's jelly), bone marrow, or adipose tissue. They differentiate into a limited range of tissues, such as bone, cartilage, and fat, and are not associated with teratoma formation.

The source of the cells also affects safety and screening requirements. For a closer comparison, see the pros and cons of autologous and allogeneic stem cells.

What Clinical Research Shows

Systematic reviews and meta-analyses of MSC trials across conditions and follow-up periods generally findno significant increase in tumor formation among recipients compared with control groups. Reported adverse events are mostly transient, such as low-grade fever or injection-site reactions.

Some caveats apply when reading these findings:

Most trials have relatively short follow-up, often one to two years. Few track patients for a decade or more.

Trials vary widely in cell source, dose, manufacturing method, and patient population, so results do not transfer evenly across products.

Cancer rates in treated patients should be compared with the baseline rate in comparable populations, not just the general public, since trial participants are often older or already ill.

Key Safety Considerations

Active or recent cancer. MSCs release growth factors and influence immune activity, including signaling molecules such as VEGF and TGF-β. In laboratory studies, these effects have raised theoretical concerns that MSCs could support tumor growth or spread in people who already have cancer. For this reason, active malignancy is a standard contraindication at reputable centers, and patients with a cancer history should consult their oncologist before treatment.

Cell manufacturing and quality. Prolonged culture expansion can, in rare cases, lead to genetic changes in cells. Reputable providers use laboratory protocols with limited expansion, sterility and viability testing, and documented quality control. Ask any clinic to describe these processes.

Quality of the evidence. Promotional material sometimes cites non-indexed journals or small, uncontrolled studies. Verify claims through indexed databases such as PubMed and ClinicalTrials.gov, and consider a second opinion from an independent physician.

Regulatory context. Most MSC treatments for chronic conditions are not approved by the U.S. FDA and are offered as investigational or off-label therapies, often outside the United States. Regulators have also warned that some unproven stem cell products have caused serious harm, usually through contamination, improper administration, or poor manufacturing rather than cancer. A closer look is available in our risk-benefit analysis of mesenchymal stem cell therapy.

Cell Therapy and Neurological or Vascular Recovery

Some patients consider cell therapy as a complement to rehabilitation after serious neurological or vascular events. Families exploring this often ask whether stroke patients can recover meaningful independence.

Recovery varies considerably with the severity and location of injury, the speed of treatment, age, and access to rehabilitation. Many people regain meaningful function, while others have lasting deficits. Published outcome figures differ between studies, so patients should discuss realistic expectations with their treating neurologist rather than rely on generalized percentages.

Cell therapy is not a substitute for rehabilitation. Evidence-based therapy remains the foundation of recovery and typically includes:

Mobility and gait training to restore balance and weight-bearing

Constraint-induced movement therapy (CIMT) to encourage use of the affected limb and promote neuroplasticity

Neuromuscular electrical stimulation to maintain muscle tone and reduce atrophy

Occupational and speech therapy to rebuild daily living skills and communication

Treatment Options and International Costs

Patients researching treatment abroad, including umbilical cord stem cell therapy in Mexico, will typically find tiered pricing based on total cell count. At R3 Stem Cell, current program ranges are approximately:

Program

Approximate Cost (USD)

Cell Count

Single outpatient protocol

$3,999 – $5,499

25–50 million

All-inclusive multi-day program

$9,499 – $12,499

100–150 million

Annual multi-visit protocol

$12,499 – $15,499

150–200 million over 4 visits

Prices are indicative and subject to change; confirm current pricing and inclusions directly with the clinic.

For a full breakdown, see the cost of stem cell treatment in Mexico. Because a higher cell count does not necessarily mean better outcomes, compare programs by evidence, quality standards, and medical oversight, not price or dose alone.

Questions to Ask Before Treatment

What is the cell source, and how are the cells processed, tested, and released?

Is the facility licensed, and which regulatory body oversees it?

What screening, including cancer screening, is done before treatment?

What published data support the treatment for my specific condition?

How are adverse events monitored and managed, and is follow-up included?

Our guide on how to choose the right stem cell clinic covers these points in more detail.

Conclusion

Current evidence suggests that properly manufactured MSC therapy does not inherently increase cancer risk, and the data in recipients without active cancer are reassuring. Still, long-term data are limited, patients with cancer or a cancer history need individualized medical advice, and quality varies widely between providers. Informed patients who complete medical screening, verify clinic credentials, and keep rehabilitation at the center of their care are best placed to make safe decisions.

Contact Us